SDRC Pilot and Feasibility Awards

 
 

2024 Pilot and Feasibility Awards

Based on our recent Pilot and Feasibility request for applications, we received 14 project proposals. With the support of MCHRI to complement the NIH P30 funding, the Stanford Diabetes Research Center (SDRC) proudly announces the following 5 awardees.

SDRC is committed to providing support for the most innovative and unique research proposals related to diabetes in all disciplines. Our goal is to support, enhance and foster new ideas that will improve how we understand, diagnose, treat and care for diabetes and its complications. The P&F program is a DRC hallmark designed to meet this goal. 

Thank you to all applicants for their submissions, and congratulations again to this year's awardees.

Antonios Chronopoulos, PhD | Instructor, Medicine, Stanford University Collaborators: Natalie J. Torok, MD, MSc and Ovijit Chaudhuri, PhD “Hyperglycemia-Induced Matrix Remodeling: A Key Modulator of CAF Heterogeneity in Liver Fibrosis and Hepatocellular Carcinogenesis”

Mindy Lee, MD, PhD | Instructor, Department of Pediatrics, Stanford University Collaborators: Priya Prahalad, MD, PhD ( Co-PI); Ramesh Johari, PhD; David Scheinker, PhD; David Maahs, MD, PhD. “Fine-Tuning of Patient Facing Messaging Using LLMs to Increase Engagement with Remote Patient Monitoring”

Debra L Safer, MD, Professor, Department of Psychiatry, Stanford University; Tracey McLaughlin, MD, Professor, Department of Medicine, Stanford University “After Tirzepatide: What happens to body composition and metabolic health?”

Sui Wang, PhD, Assistant Professor, Department of Ophthalmology, Stanford University Collaborators: Stanley Qi, PhD and Mary Elizabeth Hartnett. MD “Dissecting diabetes-induced cell-type-specific responses in human retina”

Gerlinde Wernig, MD, Assistant Professor, Department of Pathology, Stanford University Collaborators: Qiwen Deng, PhD; Jonathan Scott Maltzman, MD-PhD, FASN, FAST; Vivek Charu, MD, PhD “Investigating the Mechanisms and Therapeutic Potential of SLC4A4 in Diabetic Nephropathy”